Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

One To Watch: Chi-Med Approaches Inflection Points

Executive Summary

Hutchison China MediTech, or Chi-Med, will report pivotal or proof of concept data for savolitinib, fruquintinib and two other tyrosine kinase inhibitor candidates by Q1 2017. Having built a global cancer and inflammation R&D pipeline on the back of what started out 16 years ago as a domestic commercial botanicals business based in China, Chi-Med is now one to watch.

Advertisement

Related Content

PROFILE: Chi-Med Lays Out Broad Strategy As Fruquintinib Advances

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097066

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel